GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » Debt-to-EBITDA

Allurion Technologies (Allurion Technologies) Debt-to-EBITDA : -0.67 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Allurion Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $39.55 Mil. Allurion Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.31 Mil. Allurion Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $-62.33 Mil. Allurion Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.67.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Allurion Technologies's Debt-to-EBITDA or its related term are showing as below:

ALUR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.26   Med: -1.84   Max: -0.61
Current: -0.61

During the past 3 years, the highest Debt-to-EBITDA Ratio of Allurion Technologies was -0.61. The lowest was -3.26. And the median was -1.84.

ALUR's Debt-to-EBITDA is ranked worse than
100% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs ALUR: -0.61

Allurion Technologies Debt-to-EBITDA Historical Data

The historical data trend for Allurion Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies Debt-to-EBITDA Chart

Allurion Technologies Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
-3.26 -1.84 -0.61

Allurion Technologies Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only -1.45 -1.21 -1.00 -0.81 -0.67

Competitive Comparison of Allurion Technologies's Debt-to-EBITDA

For the Medical Devices subindustry, Allurion Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allurion Technologies's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's Debt-to-EBITDA falls into.



Allurion Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Allurion Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(39.551 + 2.306) / -69.031
=-0.61

Allurion Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(39.551 + 2.306) / -62.332
=-0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Allurion Technologies  (NYSE:ALUR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Allurion Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Allurion Technologies (Allurion Technologies) Business Description

Traded in Other Exchanges
N/A
Address
11 Huron Drive, Natick, MA, USA, 01760
Website
Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Executives
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta director, 10 percent owner 307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth officer: Chief Financial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin director C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson director 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon officer: Chief Commercial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur director, officer: Chief Executive Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani officer: Chief Medical Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760